抗真菌薬の市場規模、シェア、動向分析レポート：薬剤クラス別、適応症別、剤形別、流通チャネル別、地域別、セグメント予測、2025年～2030年

抗真菌薬市場の成長と動向：

Grand View Research社の最新レポートによると、世界の抗真菌薬の市場規模は2030年までに205億2,000万米ドルに達する見込みです。

同市場は2025年から2030年にかけてCAGR 3.92％で拡大する見込みです。世界の真菌感染症の罹患率の増加が、同市場の成長を後押しする主要因となっています。加えて、免疫抑制剤や抗悪性腫瘍剤、補綴器具や移植片、広域抗生物質の採用が増加した結果、真菌感染症の発生率が近年増加しています。

2017年に米国疾病予防管理センターが発表した統計によると、毎年、新たに22万人近くが脳感染症であるクリプトコッカス髄膜炎に罹患し、世界中で年間18万1,000人が死亡していると推定されています。死亡者のほとんどは、HIV/AIDSの高い有病率のため、サハラ以南のアフリカで報告されています。このことは、世界中で真菌感染症が多発していることから、抗真菌薬の潜在的な需要があることを示しています。

COVID-19の蔓延を食い止めるため、多くの国の政府当局は全国的な封鎖を命じた。同様に、世界各国の保健システムもサプライチェーンの維持に苦労していました。サプライチェーンの遅れは抗真菌薬の需要にも影響を及ぼしています。高齢者はHIVやがんなどの感染症や慢性疾患にかかりやすいため、世界の高齢者人口の増加は日和見真菌感染症を治療するための抗真菌薬の需要をかき立てる可能性が高いです。診断が困難で死亡率や罹患率が高い真菌感染症が増加していることから、2030年まで抗真菌剤の需要は堅調に推移すると予測されます。

抗真菌薬市場のレポートハイライト

• アゾール系薬剤クラス別が市場を席巻し、2024年の売上シェアは47.57%に達しました。この優位性は、ノキサフィル、ブフェンド、ジフルカン、クレセンバなどの主要治療薬の影響によるものです。
• カンジダ症は、免疫不全患者における罹患率の上昇と感染再発率の高さから、2024年に最大の市場シェアを占めました。
• アスペルギルス症は予測期間中に大きなCAGRを記録する見込みです。アスペルギルス症は、アスペルギルス症と呼ばれるカビによって引き起こされる感染症で、通常は呼吸器系を侵します。
• 2024年には経口薬の剤形が市場をリードしました。これは、特定の抗真菌薬が適切な摂取を確実にするために経口投与用に設計されていることに起因します。
• 病院薬局が2024年の市場をリード。病院薬局は、重要な医薬品への即時アクセスを確保する上で重要な役割を果たしています。病院薬局は外来患者と入院患者の両方にサービスを提供し、真菌感染症のシームレスな治療を促進します。
• 北米が市場を独占し、2024年には40.62％のシェアを占めました。この地域の優位性は、高度に発達したヘルスケアインフラ、手頃な価格、意識の高まりに起因します。
• アジア太平洋地域は、予測期間中に大きな成長が見込まれます。これは、対象人口の多さ、市場開拓ヘルスケア施設の存在、主要市場プレイヤーによる投資の増加によるものです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 抗真菌薬市場の変数、動向、範囲

• 市場系統の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• ビジネス環境分析
  • 業界分析- ポーターのファイブフォース分析
  • PESTLE分析
  • パイプライン分析
  • 特許満了分析
  • 価格分析

第4章 抗真菌薬市場：薬剤クラス別ビジネス分析

• 薬剤クラス別市場シェア、2024年および2030年
• 薬剤クラス別セグメントダッシュボード
• 市場規模と予測および動向分析（薬剤クラス別、2018～2030年）
• アゾール
• エキノキャンディン
• ポリエン
• アリルアミン
• その他

第5章 抗真菌薬市場：適応症別ビジネス分析

• 適応症別市場シェア、2024年および2030年
• 適応症別セグメントダッシュボード
• 市場規模、予測、動向分析（適応症別、2018～2030年）
• 皮膚糸状菌症
• アスペルギルス症
• カンジダ症
• その他

第6章 抗真菌薬市場：剤形別ビジネス分析

• 剤形別市場シェア、2024年および2030年
• 剤形別セグメントダッシュボード
• 市場規模、予測、動向分析（剤形別、2018～2030年）
• 経口薬
• 軟膏
• 粉末
• その他

第7章 抗真菌薬市場：流通チャネル別ビジネス分析

• 流通チャネル別市場シェア、2024年および2030年
• 流通チャネル別セグメントダッシュボード
• 市場規模、予測、動向分析（流通チャネル別、2018～2030年）
• 病院薬局
• 小売薬局
• その他の薬局

第8章 抗真菌薬市場：地域別推定・動向分析

• 地域別市場シェア分析、2024年および2030年
• 地域市場ダッシュボード
• 市場規模と予測動向分析、2018年から2030年まで：
• 北米
  • 国別、2018年～2030年
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東およびアフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 参入企業概要
• 企業の市況分析
• 企業分類
• 戦略マッピング
• 企業プロファイル/リスト
  • Novartis AG
  • Pfizer, Inc.
  • Bayer AG
  • Sanofi
  • Merck &Co., Inc.
  • GSK plc.
  • Abbott
  • GLENMARK
  • Enzon Pharmaceuticals, Inc.
  • Astellas Pharma, Inc.

List of Tables

• Table 1. List of secondary sources
• Table 2. List of abbreviations
• Table 3. Global Antifungal drugs market, by region, 2018 - 2030 (USD Million)
• Table 4. Global antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 5. Global antifungal drugs market, by indication, 2018 - 2030 (USD Million)
• Table 6. Global antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 7. Global antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 8. North America antifungal drugs market, by country, 2018 - 2030 (USD Million)
• Table 9. North America antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 10. North America antifungal drugs market, by indication, 2018 - 2030 (USD Million)
• Table 11. North America antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 12. North America antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 13. U.S. antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 14. U.S. antifungal drugs market, by indication, 2018 - 2030 (USD Million)
• Table 15. U.S. antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 16. U.S. antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 17. Canada antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 18. Canada antifungal drugs market, by indication, 2018 - 2030 (USD Million)
• Table 19. Canada antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 20. Canada antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 21. Mexico antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 22. Mexico antifungal drugs market, by indication, 2018 - 2030 (USD Million)
• Table 23. Mexico antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 24. Mexico antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 25. Europe antifungal drugs market, by country, 2018 - 2030 (USD Million)
• Table 26. Europe antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 27. Europe antifungal drugs market, by indication, 2018 - 2030 (USD Million)
• Table 28. Europe antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 29. Europe antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 30. UK antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 31. UK antifungal drugs market, by indication, 2018 - 2030 (USD Million)
• Table 32. UK antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 33. UK antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 34. Germany antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 35. Germany antifungal drugs market, by indication, 2018 - 2030 (USD Million)
• Table 36. Germany antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 37. Germany antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 38. France antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 39. France antifungal drugs market, by indication, 2018 - 2030 (USD Million)
• Table 40. France antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 41. France antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 42. Italy antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 43. Italy antifungal drugs market, by indication, 2018 - 2030 (USD Million)
• Table 44. Italy antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 45. Italy antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 46. Spain antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 47. Spain antifungal drugs market, by indication, 2018 - 2030 (USD Million)
• Table 48. Spain antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 49. Spain antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 50. Norway antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 51. Norway antifungal drugs market, by indication, 2018 - 2030 (USD Million)
• Table 52. Norway antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 53. Norway antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 54. Denmark antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 55. Denmark antifungal drugs market, by indication, 2018 - 2030 (USD Million)
• Table 56. Denmark antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 57. Denmark antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 58. Sweden antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 59. Sweden antifungal drugs market, by indication, 2018 - 2030 (USD Million)
• Table 60. Sweden antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 61. Sweden antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 62. Asia Pacific antifungal drugs market, by country, 2018 - 2030 (USD Million)
• Table 63. Asia Pacific antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 64. Asia Pacific antifungal drugs market, by indication, 2018 - 2030 (USD Million)
• Table 65. Asia Pacific antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 66. Asia Pacific antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 67. Japan antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 68. Japan antifungal drugs market, by indication, 2018 - 2030 (USD Million)
• Table 69. Japan antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 70. Japan antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 71. China antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 72. China antifungal drugs market, by indication, 2018 - 2030 (USD Million)
• Table 73. China antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 74. China antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 75. India antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 76. India antifungal drugs market, by indication, 2018 - 2030 (USD Million)
• Table 77. India antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 78. India antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 79. Australia antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 80. Australia antifungal drugs market, by indication, 2018 - 2030 (USD Million)
• Table 81. Australia antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 82. Australia antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 83. South Korea antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 84. South Korea antifungal drugs market, by indication, 2018 - 2030 (USD Million)
• Table 85. South Korea antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 86. South Korea antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 87. Thailand antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 88. Thailand antifungal drugs market, by indication, 2018 - 2030 (USD Million)
• Table 89. Thailand antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 90. Thailand antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 91. Latin America antifungal drugs market, by country, 2018 - 2030 (USD Million)
• Table 92. Latin America antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 93. Latin America antifungal drugs market, by indication, 2018 - 2030 (USD Million)
• Table 94. Latin America antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 95. Latin America antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 96. Brazil antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 97. Brazil antifungal drugs market, by indication, 2018 - 2030 (USD Million)
• Table 98. Brazil antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 99. Brazil antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 100. Argentina antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 101. Argentina antifungal drugs market, by indication, 2018 - 2030 (USD Million)
• Table 102. Argentina antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 103. Argentina antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 104. Middle East & Africa antifungal drugs market, by country, 2018 - 2030 (USD Million)
• Table 105. Middle East & Africa antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 106. Middle East & Africa antifungal drugs market, by indication, 2018 - 2030 (USD Million)
• Table 107. Middle East & Africa antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 108. Middle East & Africa antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 109. South Africa antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 110. South Africa antifungal drugs market, by indication, 2018 - 2030 (USD Million)
• Table 111. South Africa antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 112. South Africa antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 113. Saudi Arabia antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 114. Saudi Arabia antifungal drugs market, by indication, 2018 - 2030 (USD Million)
• Table 115. Saudi Arabia antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 116. Saudi Arabia antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 117. UAE antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 118. UAE antifungal drugs market, by indication, 2018 - 2030 (USD Million)
• Table 119. UAE antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 120. UAE antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)
• Table 121. Kuwait antifungal drugs market, by drug class, 2018 - 2030 (USD Million)
• Table 122. Kuwait antifungal drugs market, by indication, 2018 - 2030 (USD Million)
• Table 123. Kuwait antifungal drugs market, by dosage form, 2018 - 2030 (USD Million)
• Table 124. Kuwait antifungal drugs market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Antifungal drugs market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Segment snapshot
• Fig. 10 Competitive landscape
• Fig. 11 Antifungal drugs market dynamics
• Fig. 12 Antifungal drugs market: Porter's five forces analysis
• Fig. 13 Antifungal drugs market: PESTLE analysis
• Fig. 14 Drug Class market, 2018 - 2030 (USD Million)
• Fig. 15 Azoles market, 2018 - 2030 (USD Million)
• Fig. 16 Echinocandins market, 2018 - 2030 (USD Million)
• Fig. 17 Polyenes market, 2018 - 2030 (USD Million)
• Fig. 18 Allylamines market, 2018 - 2030 (USD Million)
• Fig. 19 Others market, 2018 - 2030 (USD Million)
• Fig. 20 Indication market, 2018 - 2030 (USD Million)
• Fig. 21 Dermatophytosis market, 2018 - 2030 (USD Million)
• Fig. 22 Aspergillosis market, 2018 - 2030 (USD Million)
• Fig. 23 Candidiasis market, 2018 - 2030 (USD Million)
• Fig. 24 Others market, 2018 - 2030 (USD Million)
• Fig. 25 Dosage Form market, 2018 - 2030 (USD Million)
• Fig. 26 Oral Drugs market, 2018 - 2030 (USD Million)
• Fig. 27 Ointments market, 2018 - 2030 (USD Million)
• Fig. 28 Powders market, 2018 - 2030 (USD Million)
• Fig. 29 Others market, 2018 - 2030 (USD Million)
• Fig. 30 Distribution Channel market, 2018 - 2030 (USD Million)
• Fig. 31 Hospital pharmacies market, 2018 - 2030 (USD Million)
• Fig. 32 Retail pharmacies market, 2018 - 2030 (USD Million)
• Fig. 33 Other pharmacies market, 2018 - 2030 (USD Million)
• Fig. 34 Antifungal drugs market revenue, by region
• Fig. 35 Regional marketplace: Key takeaways
• Fig. 36 North America antifungal drugs market, 2018 - 2030 (USD Million)
• Fig. 37 U.S. country dynamics
• Fig. 38 U.S. antifungal drugs market, 2018 - 2030 (USD Million)
• Fig. 39 Canada country dynamics
• Fig. 40 Canada antifungal drugs market, 2018 - 2030 (USD Million)
• Fig. 41 Mexico country dynamics
• Fig. 42 Mexico antifungal drugs market, 2018 - 2030 (USD Million)
• Fig. 43 Europe antifungal drugs market, 2018 - 2030 (USD Million)
• Fig. 44 UK country dynamics
• Fig. 45 UK antifungal drugs market, 2018 - 2030 (USD Million)
• Fig. 46 Germany country dynamics
• Fig. 47 Germany antifungal drugs market, 2018 - 2030 (USD Million)
• Fig. 48 France country dynamics
• Fig. 49 France antifungal drugs market, 2018 - 2030 (USD Million)
• Fig. 50 Italy country dynamics
• Fig. 51 Italy antifungal drugs market, 2018 - 2030 (USD Million)
• Fig. 52 Spain country dynamics
• Fig. 53 Spain antifungal drugs market, 2018 - 2030 (USD Million)
• Fig. 54 Norway country dynamics
• Fig. 55 Norway antifungal drugs market, 2018 - 2030 (USD Million)
• Fig. 56 Sweden country dynamics
• Fig. 57 Sweden antifungal drugs market, 2018 - 2030 (USD Million)
• Fig. 58 Denmark country dynamics
• Fig. 59 Denmark antifungal drugs market, 2018 - 2030 (USD Million)
• Fig. 60 Asia Pacific antifungal drugs market, 2018 - 2030 (USD Million)
• Fig. 61 Japan country dynamics
• Fig. 62 Japan antifungal drugs market, 2018 - 2030 (USD Million)
• Fig. 63 China country dynamics
• Fig. 64 China antifungal drugs market, 2018 - 2030 (USD Million)
• Fig. 65 India country dynamics
• Fig. 66 India antifungal drugs market, 2018 - 2030 (USD Million)
• Fig. 67 Australia country dynamics
• Fig. 68 Australia antifungal drugs market, 2018 - 2030 (USD Million)
• Fig. 69 South Korea country dynamics
• Fig. 70 South Korea antifungal drugs market, 2018 - 2030 (USD Million)
• Fig. 71 Thailand country dynamics
• Fig. 72 Thailand antifungal drugs market, 2018 - 2030 (USD Million)
• Fig. 73 Latin America antifungal drugs market, 2018 - 2030 (USD Million)
• Fig. 74 Brazil country dynamics
• Fig. 75 Brazil antifungal drugs market, 2018 - 2030 (USD Million)
• Fig. 76 Argentina country dynamics
• Fig. 77 Argentina antifungal drugs market, 2018 - 2030 (USD Million)
• Fig. 78 MEA antifungal drugs market, 2018 - 2030 (USD Million)
• Fig. 79 South Africa country dynamics
• Fig. 80 South Africa antifungal drugs market, 2018 - 2030 (USD Million)
• Fig. 81 Saudi Arabia country dynamics
• Fig. 82 Saudi Arabia antifungal drugs market, 2018 - 2030 (USD Million)
• Fig. 83 UAE country dynamics
• Fig. 84 UAE antifungal drugs market, 2018 - 2030 (USD Million)
• Fig. 85 Kuwait country dynamics
• Fig. 86 Kuwait antifungal drugs market, 2018 - 2030 (USD Million)
• Fig. 87 Company categorization
• Fig. 88 Company market position analysis, 2024
• Fig. 89 Strategic framework

Antifungal Drugs Market Growth & Trends:

The global antifungal drugs market size is expected to reach USD 20.52 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 3.92% from 2025 to 2030. The increasing incidence of fungal infections worldwide is the key factor stoking the growth of the market. In addition, the rise in the adoption of immunosuppressive and antineoplastic agents, prosthetic devices and grafts, and broad-spectrum antibiotics has resulted in an increased incidence of fungal infections in recent years.

According to statistics published by the Centers for Disease Control and Prevention in 2017, it has been estimated that every year, nearly 220,000 new individuals are affected by cryptococcal meningitis, which is a brain infection and has resulted in 181,000 deaths per year around the world. Most of the deaths were reported in sub-Saharan Africa, due to the high prevalence of HIV/AIDS. This indicates the potential demand for antifungal drugs due to the high prevalence of mycological infections around the globe.

The government authorities in many countries had ordered nationwide lockdowns in order to contain the spread of COVID-19. Similarly, health systems in a number of countries around the world were having trouble maintaining their supply chains. The slowness of the supply chain has also impacted the demand for antifungal medications. As aged people are more prone to infectious diseases and chronic conditions, including HIV and cancer, the rise in the geriatric population worldwide is likely to stir up the demand for antifungals to treat opportunistic fungal infections. The demand for fungistatic agents is estimated to remain strong through 2030 due to mounting cases of fungal infections that are difficult to diagnose, yielding high mortality and morbidity rates.

Antifungal Drugs Market Report Highlights:

• The Azoles drug class segment dominated the market and accounted for a revenue share of 47.57% in 2024. This dominance is attributed to the influence of key therapeutic agents, including noxafil, vfend, diflucan, and cresemba.
• The Candidiasis segment held the largest market share in 2024 due to rising incidence of the disease in immunocompromised patients and high rate of recurrent infections.
• Aspergillosis is expected to register significant CAGR during the forecast period. Aspergillosis is an infection caused by mold called aspergillosis, which usually affects the respiratory system.
• Oral drugs dosage form led the market in 2024. This is attributed to the fact that certain antifungal medications are designed for oral administration to ensure proper ingestion.
• Hospital pharmacies led the market in 2024. Hospital pharmacies play a key role in ensuring immediate access to crucial medications. They serve both out-patient and in-patient services, facilitating the seamless treatment of fungal infections.
• North America dominated the market and accounted for 40.62% share in 2024. This region dominance is attributed to the highly developed healthcare infrastructure, better affordability, and increasing awareness.
• Asia Pacific is anticipated to witness significant growth during the forecast period. This is owing to the presence of large target population, developing healthcare facilities, and increase in investments by leading market players.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Indication
  • 1.2.3. Dosage Form
  • 1.2.4. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Antifungal Drugs Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Antifungal Drugs Market: Drug Class Business Analysis

• 4.1. Drug Class Market Share, 2024 & 2030
• 4.2. Drug Class Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
• 4.4. Azoles
  • 4.4.1. Azoles Market, 2018 - 2030 (USD Million)
• 4.5. Echinocandins
  • 4.5.1. Echinocandins Market, 2018 - 2030 (USD Million)
• 4.6. Polyenes
  • 4.6.1. Polyenes Market, 2018 - 2030 (USD Million)
• 4.7. Allylamines
  • 4.7.1. Allylamines Market, 2018 - 2030 (USD Million)
• 4.8. Others
  • 4.8.1. Other Drug Class Market, 2018 - 2030 (USD Million)

Chapter 5. Antifungal Drugs Market: Indication Business Analysis

• 5.1. Indication Market Share, 2024 & 2030
• 5.2. Indication Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
• 5.4. Dermatophytosis
  • 5.4.1. Dermatophytosis Market, 2018 - 2030 (USD Million)
• 5.5. Aspergillosis
  • 5.5.1. Aspergillosis Market, 2018 - 2030 (USD Million)
• 5.6. Candidiasis
  • 5.6.1. Candidiasis Market, 2018 - 2030 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Antifungal Drugs Market: Dosage Form Business Analysis

• 6.1. Dosage Form Market Share, 2024 & 2030
• 6.2. Dosage Form Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Dosage Form, 2018 to 2030 (USD Million)
• 6.4. Oral Drugs
  • 6.4.1. Oral Drugs Market, 2018 - 2030 (USD Million)
• 6.5. Ointments
  • 6.5.1. Ointments Market, 2018 - 2030 (USD Million)
• 6.6. Powders
  • 6.6.1. Powders Market, 2018 - 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Antifungal Drugs Market: Distribution Channel Business Analysis

• 7.1. Distribution Channel Market Share, 2024 & 2030
• 7.2. Distribution Channel Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
• 7.4. Hospital Pharmacies
  • 7.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
• 7.5. Retail Pharmacies
  • 7.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
• 7.6. Other Pharmacies
  • 7.6.1. Other Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 8. Antifungal Drugs Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 8.4. North America
  • 8.4.1. North America Antifungal Drugs Market Estimates and Forecasts, By Country, 2018 - 2030 (USD Million)
  • 8.4.2. U.S.
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Target Disease Prevalence
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Reimbursement Framework
    • 8.4.2.5. U.S. Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Reimbursement Framework
    • 8.4.3.5. U.S. Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Reimbursement Framework
    • 8.4.4.5. Mexico Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Target Disease Prevalence
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement Framework
    • 8.5.2.5. Uk Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement Framework
    • 8.5.3.5. Germany Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Target Disease Prevalence
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. Reimbursement Framework
    • 8.5.4.5. France Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Target Disease Prevalence
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Reimbursement Framework
    • 8.5.5.5. Italy Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Target Disease Prevalence
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Reimbursement Framework
    • 8.5.6.5. Spain Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Target Disease Prevalence
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Reimbursement Framework
    • 8.5.7.5. Denmark Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Target Disease Prevalence
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Reimbursement Framework
    • 8.5.8.5. Sweden Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Target Disease Prevalence
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Reimbursement Framework
    • 8.5.9.5. Norway Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Target Disease Prevalence
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Reimbursement Framework
    • 8.6.2.5. Japan Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Reimbursement Framework
    • 8.6.3.5. China Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Target Disease Prevalence
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Reimbursement Framework
    • 8.6.4.5. India Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.5. Australia
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Target Disease Prevalence
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Reimbursement Framework
    • 8.6.5.5. Australia Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Target Disease Prevalence
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. Reimbursement Framework
    • 8.6.6.5. South Korea Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.7. Thailand
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Target Disease Prevalence
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Reimbursement Framework
    • 8.6.7.5. Thailand Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Target Disease Prevalence
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Reimbursement Framework
    • 8.7.2.5. Japan Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Target Disease Prevalence
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Reimbursement Framework
    • 8.7.3.5. China Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.8. Middle East and Africa
  • 8.8.1. Middle East and Africa Antifungal Drugs Market Estimates and Forecasts, 2017 - 2030 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Target Disease Prevalence
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. Reimbursement Framework
    • 8.8.2.5. South Africa Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Target Disease Prevalence
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Reimbursement Framework
    • 8.8.3.5. Saudi Arabia Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Target Disease Prevalence
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. Reimbursement Framework
    • 8.8.4.5. UAE Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Target Disease Prevalence
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Reimbursement Framework
    • 8.8.5.5. Kuwait Antifungal Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant Overview
• 9.2. Company Market Position Analysis
• 9.3. Company Categorization
• 9.4. Strategy Mapping
• 9.5. Company Profiles/Listing
  • 9.5.1. Novartis AG
    • 9.5.1.1. Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Strategic Initiatives
  • 9.5.2. Pfizer, Inc.
    • 9.5.2.1. Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Strategic Initiatives
  • 9.5.3. Bayer AG
    • 9.5.3.1. Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Strategic Initiatives
  • 9.5.4. Sanofi
    • 9.5.4.1. Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Strategic Initiatives
  • 9.5.5. Merck & Co., Inc.
    • 9.5.5.1. Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Strategic Initiatives
  • 9.5.6. GSK plc.
    • 9.5.6.1. Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Strategic Initiatives
  • 9.5.7. Abbott
    • 9.5.7.1. Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Strategic Initiatives
  • 9.5.8. GLENMARK
    • 9.5.8.1. Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Strategic Initiatives
  • 9.5.9. Enzon Pharmaceuticals, Inc.
    • 9.5.9.1. Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Strategic Initiatives
  • 9.5.10. Astellas Pharma, Inc.
    • 9.5.10.1. Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product Benchmarking
    • 9.5.10.4. Strategic Initiatives